Charles River Laboratories International (CRL) EBITDA Margin (2009 - 2026)

Charles River Laboratories International has reported EBITDA Margin for 18 years, with the latest figure at 11.94% in Q2 2026.

• On a quarterly basis, EBITDA Margin rose 224.0% year-over-year to 11.94% in Q2 2026; TTM through Jun 2026 was 2.25%, a 84.0% decrease from a year earlier, with the FY2025 full-year figure at 0.63%, down 499.0% from the prior year.
• EBITDA Margin was 11.94% for Q2 2026 at Charles River Laboratories International, down from 12.04% in the prior quarter.
• The five-year high for EBITDA Margin was 19.26% in Q2 2022, with the low at 28.51% in Q4 2025.
• Average EBITDA Margin over 5 years is 9.65%, with a median of 13.22% recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: EBITDA Margin slumped 2984 bps in 2024, then soared 445 bps in 2026.
• Over 5 years, EBITDA Margin stood at 14.89% in 2022, then dropped by 12 bps to 13.12% in 2023, then tumbled by 228 bps to 16.73% in 2024, then slumped by 70 bps to 28.51% in 2025, then soared by 142 bps to 11.94% in 2026.
• The last three EBITDA Margin figures came in at 11.94% (Q2 2026), 12.04% (Q1 2026), and 28.51% (Q4 2025), per Business Quant data.